Literature DB >> 19194631

[Diagnosis and treatment of brain metastasis].

Carlos Sajama1, José Lorenzoni, Patricio Tagle.   

Abstract

Cerebral metastasis occur in 20 to 30 percent of patients with systemic cancer and are the most common type of intracranial tumor. The median survival of untreated patients is one month with a slightly longer survival in those treated with steroids. Patients treated with whole brain radiation therapy survive between 3 to 6 months. In selected cases survival can increase to 10 to 12 months with combination of surgery and radiotherapy or stereotactic radiosurgery alone or associated to radiotherapy. Most brain metastasis arise from lung, breast and melanomas. The most important criteria for selecting patients who will benefit from surgery or stereotactic radiosurgery are a Karnofsky score of 70 or more, systemic control of the cancer and absence of leptomeningeal involvement. Surgery is indicated in patients with a single lesion located in an accessible zone and stereotactic radiosurgery is indicated for lesions up to 3 cm of diameter, and in patients with up to 3 or 4 metastasis, no matter their location. The survival benefit of chemotherapy in brain metastasis has not been demonstrated.

Entities:  

Mesh:

Year:  2009        PMID: 19194631     DOI: /S0034-98872008001000014

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  5 in total

Review 1.  [Progress of treatments in non-small cell lung cancer with brain metastases].

Authors:  Chunhua Ma; Rong Jiang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-05

2.  [Impact of CT/MRI image registration on target delineation of radiotherapy for lung cancer with brain metastasis].

Authors:  Yang Li; Xianglan Li; Yewei Wang; Yang Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-08

3.  [China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)].

Authors:  Yuankai Shi; Yan Sun; Jinming Yu; Cuimin Ding; Ziping Wang; Changli Wang; Dong Wang; Cunde Wang; Zheng Wang; Mengzhao Wang; Xiuyi Zhi; You Lu; Jifeng Feng; Yunpeng Liu; Xiaoqing Liu; Wei Liu; Gang Wu; Xiaomei Li; Kai Li; Enxiao Li; Wei Li; Gongyan Chen; Zhengtang Chen; Ping Yu; Ning Wu; Milu Wu; Wenhua Xiao; Li Zhang; Yiping Zhang; Shucai Zhang; Shujun Yang; Xia Song; Dongmei Lin; Rongcheng Luo; Li Shan; Caicun Zhou; Zongmei Zhou; Qiong Zhao; Chengping Hu; Yi Hu; Qisen Guo; Jianhua Chang; Cheng Huang; Xuan Zeng; Baohui Han; Xiaohong Han; Bo Jia; Ying Han; Yu Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-01

4.  Characterization of genetic alterations in brain metastases from non-small cell lung cancer.

Authors:  Li Liao; Xiaoyu Ji; Mengxi Ge; Qiong Zhan; Ruofan Huang; Xiaohua Liang; Xinli Zhou
Journal:  FEBS Open Bio       Date:  2018-08-30       Impact factor: 2.693

5.  PSPH Mediates the Metastasis and Proliferation of Non-small Cell Lung Cancer through MAPK Signaling Pathways.

Authors:  Li Liao; Mengxi Ge; Qiong Zhan; Ruofan Huang; Xiaoyu Ji; Xiaohua Liang; Xinli Zhou
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.